{"preliminary_commentary":{"by_channel":{"bluesky_thread":27,"youtube":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04523857\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ABBY","nct_id":"NCT04523857","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=abby-nct04523857. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ABBY","arms":[{"description":"Abemaciclib (150 mg BID)","label":"A (Abema)","type":"EXPERIMENTAL"},{"description":"Abemaciclib (100 mg or 150 mg BID\\*) + Hydroxychloroquine (600 mg BID)\n\n\\*Abemaciclib dose will be determined by safety cohort","label":"B (Abema + HCQ)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":44,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Abemaciclib","otherNames":["Verzenio"],"type":"DRUG"},{"name":"Hydroxychloroquine","otherNames":["Plaquenil"],"type":"DRUG"}],"last_update":"2026-05-26","lead_sponsor":"Abramson Cancer Center at Penn Medicine","official_title":"A Phase II Pilot Trial of ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer Patients (\"ABBY\")","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of treatment-emergent adverse events during cycle 1 of the safety cohort (safety of combination HCQ + Abema)","timeFrame":"Toxicity is assessed over the first cycle (4 weeks) of treatment"},{"measure":"Change in bone marrow DTC number evaluated by DTC-IHC assay after 6 cycles of therapy compared to baseline (Efficacy of Abema +/- HCQ in eliminating bone marrow DTCs)","timeFrame":"6 cycles (approximately 6 months)"}],"references":[],"start_date":{"date":"2021-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04523857"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/abby-nct04523857"}